FDA expands use for ArthoCare's RF (radiofrequency) tools:
This article was originally published in Clinica
ArthroCare has received US FDA marketing clearance to expand the use of its radiofrequency (RF) arthroscopic surgical devices. The Sunnyvale, California firm has gained the go-ahead to use its Coblation-based disposable surgical devices in over 40 specific arthroscopic indications in the knee, shoulder, wrist, ankle, elbow and hip. The expanded clearance covers around 160 orthopaedic procedures and represents the broadest array of specific indications approved for any company marketing RF surgical equipment for arthroscopic and orthopaedic applications, the company claims. The devices were previously cleared for soft tissue resection, ablation, coagulation and haemostasis in general arthroscopic and orthopaedic procedures.
You may also be interested in...
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.